WuXi Biologics proposed spin-off and a separate HKEX listing of its subsidiary WuXi XDC means the company will be able to better capture the fast-growing global bioconjugate market.
List view / Grid view
Discover what is driving the oligonucleotide therapeutics sector as scientists navigate challenges such as financing and success-to-market.
Operation has begun for CRDMO WuXi STA's first continuous manufacturing line for oral solids, in Wuxi city, China.
The new 190-acre pharmaceutical manufacturing campus will provide formulation development, clinical and commercial drug product manufacturing services.